Effect of recombinant growth hormone on growth and chondrocyte dynamics in children with Inflammatory bowel disease (IBD) and growth failure. - rhGH in IBD

Royal Hospital For Sick Children, Yorkhill Division0 个研究点目标入组 60 人开始时间: 2005年2月17日最近更新: 2019年12月10日

试验速览

暂无简介。

•Diagnosis of IBD
•Height Velocity SDS of less than –0.5 over 6 months prior to study.
•Patients of all ages will be eligible but boys and girls with significant pubertal delay shall only be eligible after a period of treatment with sex steroids
•Written informed consent
•Are the trial subjects under 18? yes
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Previous treatment with rhGH
•Diabetes mellitus or history of significant glucose intolerance (fasting blood glucose>5.5mmol/l)
•Endocrinopathy other than GHD
•Bowel surgery within last 6 months
•Active malignancy
•Ongoing anti-cancer therapy
•Benign intracranial hypertension.
•Severe arterial hypertension, defined as diastolic blood pressure > 110 mmHg with or without antihypertensive treatment.
•Known or suspected allergy to the trial product or related products.
•Lactation/pregnancy or intent to become pregnant during the planned trial period.

发起方

Royal Hospital For Sick Children, Yorkhill Division